0001193125-23-276662.txt : 20231114 0001193125-23-276662.hdr.sgml : 20231114 20231114074031 ACCESSION NUMBER: 0001193125-23-276662 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alaunos Therapeutics, Inc. CENTRAL INDEX KEY: 0001107421 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841475642 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33038 FILM NUMBER: 231401610 BUSINESS ADDRESS: STREET 1: 8030 EL RIO STREET CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: (346) 355-4099 MAIL ADDRESS: STREET 1: 8030 EL RIO STREET CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: ZIOPHARM ONCOLOGY INC DATE OF NAME CHANGE: 20050919 FORMER COMPANY: FORMER CONFORMED NAME: EASYWEB INC DATE OF NAME CHANGE: 20010213 8-K 1 d349273d8k.htm 8-K 8-K
false 0001107421 0001107421 2023-11-08 2023-11-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 8, 2023

 

 

Alaunos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-33038   84-1475642

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

8030 El Rio Street

Houston, TX 77054

(Address of principal executive offices, including zip code)

(346) 355-4099

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   TCRT   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On November 14, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial condition and results of operations for the three months ended September 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 2.02, including Exhibit 99.1, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

 

Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously disclosed, on January 4, 2023, the Company received a deficiency letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company was provided an initial period of 180 calendar days, or until July 3, 2023 (the “Compliance Date”), to regain compliance with the Bid Price Requirement.

On June 22, 2023, the Company applied to transfer the listing of the Common Stock from the Nasdaq Global Select Market to the Nasdaq Capital Market (the “Transfer”). On July 5, 2023, Nasdaq notified the Company that the Transfer was approved, and that, in connection with the Transfer, the Company was eligible for an additional 180 calendar day period, or until January 2, 2024 (the “Extended Compliance Period”), to regain compliance with the Bid Price Requirement.

On November 8, 2023, the Company received a Staff Delisting Determination letter (the “Delisting Determination”) from the Staff notifying the Company that, because the closing bid price for the Common Stock was below $0.10 per share for 10 consecutive trading days during the Extended Compliance Period, the Staff has determined to suspend trading of the Common Stock on Nasdaq pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iii), effective November 17, 2023, and file a Form 25-NSE with the Securities and Exchange Commission (the “SEC”) to remove the Common Stock from listing and registration under the Securities Exchange Act of 1934, as amended, unless the Company timely requests an appeal of the Delisting Determination to a Nasdaq Hearings Panel (the “Panel”).

We intend to timely request a hearing before the Panel to appeal the Delisting Determination and expect a hearing before the Panel to be scheduled where we will seek to remain listed until we are able to consummate a strategic transaction, if ever. Following the hearing, if granted, the Company expects the Panel to issue a written decision that will determine whether the Common Stock will remain listed on Nasdaq.

A timely request for a hearing ordinarily stays the suspension or delisting of the Common Stock, so the Company expects that the Common Stock will continue to trade on the Nasdaq Capital Market under the symbol “TCRT” while the appeal process is pending.

There can be no assurance that the Company’s plan will be accepted by the Panel or that, if it is, the Company will be able to regain compliance with the applicable Nasdaq listing requirements. If the Common Stock is delisted, it could be more difficult to buy or sell the Common Stock or to obtain accurate quotations, and the price of the Common Stock could suffer a material decline. Delisting could also impair the Company’s ability to raise capital.

Forward-Looking Statements

This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the U.S. federal securities laws. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. Examples of forward-looking statements in this Form 8-K include, without limitation, statements regarding whether the Company will request a review of the Delisting Determination and the timing of the filing of any Form 25-NSE with the SEC. Forward-looking statements are statements that are not historical facts, nor assurances of future performance. Instead, they are based on the Company’s current beliefs, expectations and assumptions regarding the future of its business, future plans, strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent risks and uncertainties, and actual results may differ materially from those set forth in the forward-looking statements. Important factors that could cause actual results to differ include, without limitation, delisting from Nasdaq may adversely impact trading in the Common Stock and the Company’s ability to raise financing; the Company has and expects to continue to incur significant losses; the Company’s need for additional funding, which may not be available on reasonable terms or at all; and the other important factors described under the caption “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the SEC on November 14, 2023, and its other filings with the SEC. Any forward-looking statement made by the Company in this Form 8-K is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, the Company expressly disclaims any obligation to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
No.		   

Description

99.1    Press Release of Alaunos Therapeutics, Inc., dated November 14, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

   Alaunos Therapeutics, Inc.
Date: November 14, 2023  

 

   By:  

/s/ Melinda Lackey

 

 

   Name:   Melinda Lackey
 

 

   Title:   Senior Vice President, Legal and Administration
 EX-99.1 2 d349273dex991.htm EX-99.1 EX-99.1
LOGO    Exhibit 99.1

Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives

 

  •  

TCR-T Library Phase 1/2 trial achieved an 87% disease control rate of eight evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all treated patients

 

  •  

hunTR® discovered new HLA class I and class II restricted TCRs that recognize driver mutations, including KRAS and TP53

 

  •  

Company continues to explore potential strategic alternatives; cost-savings measures expected to extend cash runaway into the second quarter of 2024

HOUSTON, November 14, 2023 – Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the third quarter ended September 30, 2023. As previously announced, the Company is exploring strategic alternatives with Cantor Fitzgerald & Co. as its strategic advisor. Alaunos continues to reduce spend and cost-savings measures taken to date are expected to extend its cash runway into the second quarter of 2024.

Operational & Corporate Update

Clinical Data from TCR-T Library Phase 1/2 Trial: Eight patients were treated and evaluated in the Company’s TCR-T Library Phase 1/2 Trial. Patients with pancreatic (3), colorectal (4) and non-small cell lung cancer (1) were treated, with certain of the pancreatic and colorectal patients also having lung metastases. Overall, the trial showed the Company’s T cells were well-tolerated in all evaluable participants with no dose-limiting toxicities (DLTs) and no immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. All cytokine release syndrome (CRS) events were within grades 1-3 and were self-limiting or resolved with standard clinical management and, in some cases, a single dose of tocilizumab.

One patient with non-small cell lung cancer (NSCLC) achieved an objective partial response with six months progression-free survival. Six other patients achieved best overall response of stable disease. The total overall response rate was 13% and disease control rate was 87% in evaluable patients with advanced, metastatic, refractory solid tumors (see attached figure). Disease control was measured by objective responses and stable disease. Increased secretion of interferon-gamma relative to baseline was detected in all patients’ serum post-cell transfer suggesting recognition of the tumor by the infused TCR-T cells. Persistence of TCR-T cells in peripheral blood was detected in all evaluable patients at their last follow-up, including up to six months in one patient. Infiltration of TCR-T cells into the tumor was also detected in three samples where a fresh biopsy was collected suggesting homing to the tumor microenvironment. All patients have progressed or withdrawn from the trial and long-term follow-up is ongoing for a subset of patients with no further intervention per the treatment protocol. This trial established proof-of-concept that Sleeping Beauty TCR-T cells can result in objective clinical responses and recognize established tumors in vivo.

Despite the encouraging TCR-T Library Phase 1/2 Trial data, based on the substantial cost to continue development and the current financing environment, Alaunos announced in August 2023 that it would not pursue any further development of its clinical programs.

hunTR® TCR Discovery Platform Identifies Proprietary TCRs: Alaunos has discovered multiple proprietary TCRs targeting driver mutations through its hunTR® TCR discovery platform. In addition to TCRs that recognize KRAS and TP53 mutations similar to those licensed from the National Cancer Institute, the Company identified additional TCRs that bind to other driver mutations and TCRs that are restricted to additional HLAs. Alaunos believes that the hunTR® library has the potential to allow for the treatment of a large patient population.

Strategic Alternatives: The Company continues to explore strategic alternatives, which may include but are not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. In connection with the strategic reprioritization, the Company has reduced its workforce by approximately 80% to date in order to streamline the organization and to maximize its cash runway.

Third Quarter Ended September 30, 2023, Financial Results

Collaboration Revenue: Collaboration revenue was $0 for the third quarter of 2023, compared to $2.9 million for the third quarter of 2022. The decrease was due to revenue earned under the Solasia License and Collaboration Agreement in 2022 that did not recur in 2023.

Research and Development Expenses: Research and development expenses were $3.7 million for the third quarter of 2023, compared to $7.9 million for the third quarter of 2022, a decrease of approximately 54%. The decrease was primarily due to lower program expenses of $0.8 million as a result of our wind-down of clinical activities, a $0.6 million decrease in employee-related expenses due to our reduced headcount, an accrual adjustment related to our de-prioritized clinical programs of $0.3 million and a $2.5 million milestone payment to MD Anderson in 2022 under the terms of our patent and technology license agreement that did not recur in 2023.

General and Administrative Expenses: General and administrative expenses were $3.6 million for the third quarter of 2023, compared to $3.3 million for the third quarter of 2022, an increase of approximately 9%. The increase was primarily due to higher consulting and professional services expenses of $0.9 million related to increased legal costs, partially offset by a $0.4 million decrease in employee-related expenses due to our reduced headcount and a $0.2 million decrease in insurance fees.

Restructuring Costs: Restructuring costs were $0.4 million for the third quarter of 2023, compared to $0 for the third quarter of 2022 due to severance expenses for terminated employees related to our strategic reprioritization announced in August 2023.

Property and Equipment and Right-of-Use Asset Impairment: Property and equipment and right-of-use asset impairment charges were $1.0 million for the third quarter of 2023, compared to $0 for the third quarter of 2022 due to changes in the intended use of our property and equipment and lease right-of-use asset following the announcement of our strategic reprioritization in August 2023.

Net Loss: Net loss was $8.5 million, or $(0.04) per share, for the third quarter of 2023, compared to a net loss of $8.9 million, or $(0.04) per share, for the third quarter in 2022.

Cash, Cash Equivalents and Restricted Cash: As of September 30, 2023, Alaunos had approximately $11.9 million in cash balances. The Company expects to have sufficient cash resources to fund operations into the second quarter of 2024 as a result of its ongoing strategic reprioritization.

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics is a T-cell receptor (TCR) cell therapy company powered by its hunTR® (human neoantigen T-cell Receptor) discovery platform. hunTR® enables the rapid identification of wholly owned, proprietary TCRs. Using a proprietary high-throughput TCR screening process, hunTR® enables rapid functional validation of TCRs potentially allowing Alaunos to advance new TCRs from the lab to testing in the clinic. For more information, visit www.alaunos.com.

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” “believes” or other words or terms of similar meaning. These statements include, but are not limited to, statements regarding the Company’s ability to successfully implement its strategic reprioritization or realize any or all of the anticipated benefits once implemented and its ability to successfully consummate any strategic transactions; the completion and impact of the reduction in workforce; the planned renewed focus on the hunTR® TCR discovery platform and its success, including its ability to discover additional TCRs and the ability to monetize any newly discovered TCRs; the wind down of the TCR-T Phase 1/2 Library trial; the Company’s expected cash runway; and the results and potential of the TCR-T Phase 1/2 Library trial and the hunTR® discovery platform. Although the management team of Alaunos believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Alaunos, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, among other things, risks relating to volatility and uncertainty in the capital markets for biotechnology and cell therapy companies; availability of suitable third parties with which to conduct contemplated strategic transactions; whether the Company will be able to pursue a strategic transaction, or whether any transaction, if pursued, will be completed successfully and on attractive terms or at all; whether our cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital requirements; changes in the Company’s operating plans that may impact its cash expenditures; the uncertainties inherent in research and development, future clinical data and analysis; the risks associated with reductions in workforce, including reduced morale and attrition of additional employees necessary for the strategic reprioritization; the Company’s exclusive focus on its hunTR® TCR discovery platform; the strength and enforceability of Alaunos’ intellectual property rights; competition from other pharmaceutical and biotechnology companies; and the potential delisting of the Company’s common stock from the Nasdaq Stock Market LLC, as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Alaunos, including those risks and uncertainties listed in the most recent periodic report filed by Alaunos with the Securities and Exchange Commission. Alaunos is providing this information as of the date of this press release, and Alaunos does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

Investor Relations Contact:

ir@alaunos.com

LOGO

Alaunos Therapeutics, Inc.

Statement of Operations

(In thousands except per share data)

 

     For the Three Months Ended
September 30
(Unaudited)		  
     2023     2022  

Collaboration revenue

    $ —       $ 2,911  

Operating expenses:

     

Research and development

    $ 3,656     $ 7,893  

General and administrative

      3,578       3,282  

Restructuring costs

      419       —    

Property and equipment and right-of-use asset impairment

      1,011       —    

Total operating expenses

      8,664       11,175  

Loss from operations

      (8,664 )      (8,264 ) 

Interest expense

      —         (841 ) 

Other income, net

      188       254  

Net loss

      (8,476 )      (8,851 ) 

Basic and diluted net loss per share

    $ (0.04 )    $ (0.04 ) 

Weighted average common shares outstanding, basic and diluted

      240,046,026       215,098,995  

Alaunos Therapeutics, Inc.

Selected Balance Sheet Data

(In thousands)

 

     September 30,
2023
(Unaudited)		      December 31,
2022
(Audited)		  

Cash and cash equivalents

    $ 11,944      $ 39,058  

Restricted cash

    $ —        $ 13,938  

Working capital, excluding restricted cash

    $ 8,193      $ 15,695  

Total assets

    $ 19,440      $ 64,937  

Total stockholders’ equity

    $ 13,900      $ 38,555  
 EX-101.SCH 3 tcrt-20231108.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 tcrt-20231108_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 tcrt-20231108_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g349273g1114053540962.jpg GRAPHIC begin 644 g349273g1114053540962.jpg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end GRAPHIC 7 g349273g1114053542380.jpg GRAPHIC begin 644 g349273g1114053542380.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 08, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001107421
Document Type 8-K
Document Period End Date Nov. 08, 2023
Entity Registrant Name Alaunos Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-33038
Entity Tax Identification Number 84-1475642
Entity Address, Address Line One 8030 El Rio Street
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77054
City Area Code (346)
Local Phone Number 355-4099
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol TCRT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 9 d349273d8k_htm.xml IDEA: XBRL DOCUMENT 0001107421 2023-11-08 2023-11-08 false 0001107421 8-K 2023-11-08 Alaunos Therapeutics, Inc. DE 001-33038 84-1475642 8030 El Rio Street Houston TX 77054 (346) 355-4099 false false false false Common Stock, par value $0.001 per share TCRT NASDAQ false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d349273d8k.htm tcrt-20231108.xsd tcrt-20231108_lab.xml tcrt-20231108_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d349273d8k.htm": { "nsprefix": "tcrt", "nsuri": "http://alaunos.com/20231108", "dts": { "inline": { "local": [ "d349273d8k.htm" ] }, "schema": { "local": [ "tcrt-20231108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "tcrt-20231108_lab.xml" ] }, "presentationLink": { "local": [ "tcrt-20231108_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "report": { "R1": { "role": "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-08_to_2023-11-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d349273d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-08_to_2023-11-08", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d349273d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://alaunos.com//20231108/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001193125-23-276662-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-276662-xbrl.zip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end